IRIDEX Cyclo G6 Laser System receives FDA clearance for treatment of glaucoma
IRIDEX Corporation today announced that it has received clearance from the U.S. Food and Drug Administration to market its first laser system designed solely for use in treating glaucoma and its symptoms. Specifically, the Company was granted 510(k) clearance for the IRIDEX Cyclo G6 Laser System (with delivery devices).